Total Payments
$404,947
2024 Payments
$2,218
Companies
39
Transactions
846
Medicare Patients
1,786
Medicare Billing
$283,686
Payment Breakdown by Category
Other$239,058 (59.0%)
Consulting$79,517 (19.6%)
Travel$39,834 (9.8%)
Research$24,599 (6.1%)
Food & Beverage$21,635 (5.3%)
Education$303.33 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $194,908 | 84 | 48.1% |
| Consulting Fee | $79,517 | 28 | 19.6% |
| Honoraria | $44,150 | 26 | 10.9% |
| Travel and Lodging | $39,834 | 202 | 9.8% |
| Unspecified | $24,599 | 11 | 6.1% |
| Food and Beverage | $21,635 | 488 | 5.3% |
| Education | $303.33 | 7 | 0.1% |
Payments by Type
General
$380,347
835 transactions
Research
$24,599
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $102,982 | 127 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $80,580 | 144 | $0 (2024) |
| Lundbeck LLC | $52,026 | 84 | $0 (2019) |
| ACADIA Pharmaceuticals Inc | $39,400 | 78 | $0 (2024) |
| US WorldMeds, LLC | $30,863 | 74 | $0 (2020) |
| Eli Lilly and Company | $28,506 | 16 | $0 (2020) |
| Acorda Therapeutics, Inc | $27,066 | 50 | $0 (2024) |
| Amneal Pharmaceuticals LLC | $14,271 | 39 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $7,135 | 12 | $0 (2022) |
| MDD US Operations, LLC | $5,420 | 29 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,218 | 54 | Merz Pharmaceuticals, LLC ($355.53) |
| 2023 | $13,800 | 55 | Neurocrine Biosciences, Inc. ($7,976) |
| 2022 | $22,599 | 93 | Neurocrine Biosciences, Inc. ($6,218) |
| 2021 | $45,453 | 70 | Neurocrine Biosciences, Inc. ($21,432) |
| 2020 | $22,990 | 57 | Teva Pharmaceuticals USA, Inc. ($10,687) |
| 2019 | $93,375 | 184 | Neurocrine Biosciences, Inc. ($28,927) |
| 2018 | $112,497 | 181 | Lundbeck LLC ($40,759) |
| 2017 | $92,015 | 152 | Teva Pharmaceuticals USA, Inc. ($34,733) |
All Payment Transactions
846 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 12/11/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $10.74 | General |
| Category: NEUROLOGY | ||||||
| 11/21/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $12.24 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/12/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $108.03 | General |
| Category: Central Nervous System | ||||||
| 11/05/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $15.85 | General |
| Category: NEUROSCIENCE | ||||||
| 10/18/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $12.11 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 10/14/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $80.45 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 10/09/2024 | Merz Pharmaceuticals, LLC | INBRIJA (Drug) | Food and Beverage | In-kind items and services | $124.57 | General |
| Category: Parkinson's Disease | ||||||
| 10/09/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $8.04 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 09/30/2024 | Amneal Pharmaceuticals LLC | — | Food and Beverage | In-kind items and services | $83.88 | General |
| 09/30/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $32.00 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 09/29/2024 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $122.36 | General |
| 09/28/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug), RADICAVA ORS | Food and Beverage | In-kind items and services | $99.97 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 09/27/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $58.79 | General |
| Category: Neuropsychiatry | ||||||
| 09/27/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $11.43 | General |
| Category: Neuropsychiatry | ||||||
| 09/27/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $7.83 | General |
| Category: Neuropsychiatry | ||||||
| 09/27/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $1.85 | General |
| Category: Neuropsychiatry | ||||||
| 09/19/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $80.58 | General |
| Category: Central Nervous System | ||||||
| 09/13/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $12.77 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 08/16/2024 | ABBVIE INC. | DUOPA (Drug) | Food and Beverage | In-kind items and services | $109.79 | General |
| Category: NEUROSCIENCE | ||||||
| 08/15/2024 | Amneal Pharmaceuticals LLC | RYTARY (Drug) | Food and Beverage | In-kind items and services | $10.10 | General |
| Category: NEUROLOGY | ||||||
| 08/09/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | In-kind items and services | $18.53 | General |
| Category: Adenosine A2A Receptors | ||||||
| 08/08/2024 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $115.63 | General |
| Category: Neurology | ||||||
| 07/30/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $42.75 | General |
| Category: Musculoskeletal | ||||||
| 07/16/2024 | Amneal Pharmaceuticals LLC | RYTARY (Drug) | Food and Beverage | In-kind items and services | $21.77 | General |
| Category: NEUROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EFFECT OF LY3154207 ON COGNITION IN MILD TO MODERATE PARKINSONS DISEASE DEMENTIA PDD - THE PRESENCE STUDY | Eli Lilly and Company | $23,815 | 3 |
| Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease | Biogen, Inc. | $122.54 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 395 | 552 | $156,857 | $56,723 |
| 2022 | 5 | 387 | 586 | $162,672 | $61,356 |
| 2021 | 9 | 464 | 4,506 | $217,097 | $77,918 |
| 2020 | 12 | 540 | 8,151 | $269,975 | $87,689 |
Total Patients
1,786
Total Services
13,795
Medicare Billing
$283,686
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 131 | 214 | $72,332 | $27,034 | 37.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 148 | 205 | $51,455 | $18,696 | 36.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 29 | 29 | $13,978 | $4,559 | 32.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 59 | 70 | $11,970 | $4,556 | 38.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $5,362 | $1,389 | 25.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 14 | 20 | $1,760 | $488.33 | 27.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 147 | 269 | $90,922 | $35,510 | 39.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 123 | 168 | $42,168 | $15,519 | 36.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 75 | 94 | $16,074 | $5,884 | 36.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 22 | 22 | $10,604 | $3,595 | 33.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 20 | 33 | $2,904 | $848.50 | 29.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 108 | 166 | $56,108 | $22,776 | 40.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 147 | 211 | $52,961 | $19,379 | 36.6% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 12 | 3,900 | $59,370 | $18,944 | 31.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 87 | 107 | $18,297 | $6,559 | 35.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 38 | 38 | $18,316 | $6,248 | 34.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 11 | 11 | $4,213 | $1,460 | 34.7% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 24 | 29 | $4,147 | $1,134 | 27.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 26 | 33 | $2,904 | $847.74 | 29.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 11 | 11 | $781.00 | $570.30 | 73.0% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2020 | 22 | 7,450 | $113,835 | $35,465 | 31.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 154 | 231 | $57,981 | $17,798 | 30.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 110 | 158 | $27,018 | $8,639 | 32.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 60 | 82 | $27,716 | $8,365 | 30.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 51 | 64 | $4,544 | $3,571 | 78.6% |
About Dr. David Shprecher, D.O
Dr. David Shprecher, D.O is a Neurology healthcare provider based in Sun City, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/29/2007. The National Provider Identifier (NPI) number assigned to this provider is 1679692594.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Shprecher, D.O has received a total of $404,947 in payments from pharmaceutical and medical device companies, with $2,218 received in 2024. These payments were reported across 846 transactions from 39 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($194,908).
As a Medicare-enrolled provider, Shprecher has provided services to 1,786 Medicare beneficiaries, totaling 13,795 services with total Medicare billing of $283,686. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology, Neurology
- Location Sun City, AZ
- Active Since 03/29/2007
- Last Updated 09/04/2024
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1679692594
Products in Payments
- AUSTEDO (Drug) $76,984
- INGREZZA (Drug) $74,056
- NORTHERA (Drug) $52,026
- NUPLAZID (Drug) $39,298
- INBRIJA (Drug) $26,897
- SD809-TD (Drug) $25,110
- Xadago (Drug) $20,710
- RYTARY (Drug) $9,960
- APOKYN (Drug) $9,422
- ONGENTYS (Drug) $4,592
- APTIOM (Drug) $3,418
- KYNMOBI (Drug) $2,569
- DUOPA (Drug) $2,052
- DYSPORT (Drug) $604.76
- SD809-HD (Drug) $604.70
- MYOBLOC (Biological) $498.88
- Xeomin (Biological) $463.26
- Dysport (Drug) $294.96
- ACTIVA (Device) $270.48
- Nayzilam (Drug) $240.63
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Sun City
Holly Laub, Do, DO
Neurology — Payments: $36,188
Neurology $36,188
Dr. Maninder Kahlon, M.d, M.D
Neurology — Payments: $20,855
Neurology $20,855
Sara Dhanani, M.d, M.D
Neurology — Payments: $17,103
Neurology $17,103
Dr. Brandon Woods, Md, MD
Neurology — Payments: $8,386
Neurology $8,386
Seth Larson, Md, MD
Neurology — Payments: $722.23
Neurology $722.23
Dr. Kenneth Harris, Md, MD
Neurology — Payments: $48.99
Neurology $48.99